Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer
Göster/ Aç
Erişim
info:eu-repo/semantics/embargoedAccessTarih
2023Yazar
Göktaş Aydın, SabinBilici, Ahmet
Çalış, Elif
Kutlu, Yasin
Hamdard, Jamshid
Muğlu, Harun
Ölmez, Ömer Fatih
Karcı, Ebru
Açıkgöz, Özgür
Üst veri
Tüm öğe kaydını gösterKünye
Göktaş Aydın, S., Bilici, A., Çalış, E., Kutlu, Y., Hamdard, J., Muğlu, H. ... Açıkgöz, Ö. (2023). Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer. International Immunopharmacology, 124. https://doi.org/10.1016/j.intimp.2023.110947Özet
Background: Non-small cell lung cancer (NSCLC) often exhibits elevated Secreted Protein Acidic and Cysteine-Rich (SPARC) expression. In this study, we investigated the impact of SPARC expression on clinicopathologic features, pembrolizumab response, and prognosis in metastatic NSCLC patients. Methods: Thirty-six patients diagnosed with metastatic NSCLC without actionable driver mutation and who received pembrolizumab with or without chemotherapy were included in this study. PD-L1 and SPARC expression were evaluated, with PD-L1 expression categorized based on tumor proportion score and SPARC staining intensity graded as 1+, 2+, and 3 +. Patients’ characteristics were compared across groups, and possible predictive markers were determined by binary logistic regression analysis. Results: No significant associations were found between SPARC expression and smoking status, histopathological tumor type, T and N status, and liver and bone metastasis. Higher SPARC expression was significantly linked to lower brain metastasis rates but higher CNS progression rates (p = 0.022 and p = 0.011, respectively. The objective response rate (ORR) showed a trend of being higher in the SPARC 1 + group (85.7% vs. 43.8% and 50.0% in 2 + and 3 + groups, respectively, p = 0.052. Univariate analysis did not find SPARC expression to be a significant prognostic factor for progression-free survival (PFS) (p = 0.7) and overall survival (OS) (p = 0.07).SPARC 1 + expression negatively affected the pembrolizumab response(p = 0.04,OR:0.11, 95%CI 0.01–0.92). Conclusions: Our study sheds light on a novel aspect of SPARC expression as a potential predictor of pembrolizumab response and a marker for CNS progression in metastatic NSCLC patients treated in the first-line setting.
WoS Q Kategorisi
Q1Scopus Q Kategorisi
Q1Kaynak
International ImmunopharmacologyCilt
124Koleksiyonlar
- Makale Koleksiyonu [3655]
- PubMed İndeksli Yayınlar Koleksiyonu [4054]
- Scopus İndeksli Yayınlar Koleksiyonu [6295]
- WoS İndeksli Yayınlar Koleksiyonu [6436]